Drug patent expirations through 2035 open market for generics and biosimilars

Patent expirations approach

The global pharmaceutical industry is heading toward an unusually large wave of drug patent expirations through 2035. Le Monde describes the coming period as a patent cliff: a concentrated loss of intellectual-property protection that could significantly alter competition between branded medicines, generics and biosimilars.

Patents give their holders a period of protection from direct copies. Once that protection expires, other manufacturers can seek to market competing versions, subject to the applicable regulatory requirements. The commercial consequences can be substantial because products that previously faced limited direct competition may have to compete with lower-priced alternatives.

The scale and timing of the approaching expirations make this more than a series of isolated product events. They create a long pipeline of potential market entries extending to 2035. For producers of branded medicines, that means revenue pressure may emerge across multiple portfolios. For manufacturers specializing in generics and biosimilars, it means a broader field of products that could become commercially accessible.

Different openings for generics and biosimilars

Generic medicines and biosimilars address different types of products. A generic is intended to compete with a conventional medicine after relevant protection ends. A biosimilar is developed as a highly similar alternative to an existing biological medicine. The latter category involves more complex products and therefore presents different development, manufacturing and regulatory demands.

The patent cliff is nevertheless an opportunity for both groups. Companies able to select viable products, complete development and secure regulatory clearance can enter markets previously controlled by originator companies. The opportunity is not automatic: manufacturers must still demonstrate that their products meet the required standards and must build sufficient production capacity to serve customers reliably.

Competition may also differ from product to product. Some expired patents could attract several entrants, intensifying price pressure. Others may draw fewer competitors because development or production is more demanding. Investors, producers and buyers will therefore need to assess each medicine separately rather than treat the entire expiration wave as one uniform market.

Pressure on branded-drug strategies

For originator laboratories, the central challenge is replacing revenue from medicines losing protection. The approaching expirations can influence research priorities, product-development decisions and corporate transactions. Companies may seek new medicines, additional protected uses or other assets capable of supporting future sales, but the available source material does not identify specific transactions or products.

Generic and biosimilar entry can also create savings for healthcare systems and purchasers, according to Le Monde. Competition gives hospitals, pharmacies and other buyers alternatives to the original medicine. The size of any saving will depend on the number of entrants, production economics, regulation and purchasing arrangements in each market.

A market reshaped over several years

The effects will unfold gradually rather than on a single date. Every medicine has its own patent position, regulatory pathway and manufacturing requirements. Legal disputes or additional protections may also affect when a competitor can actually reach the market, even when a principal patent expires.

Through 2035, the industry will be divided between companies defending established brands, producers preparing competing versions and buyers assessing new supply options. The patent cliff will reward manufacturers that combine timely product selection with regulatory execution and dependable capacity. It will put the greatest pressure on branded-drug companies that cannot replace sales exposed to new competition.